Benlysta at lasta: GSK finally snares HGS at $14 a share
This article was originally published in Scrip
After months of wrangling and hostility, Human Genome Sciences has at last accepted GlaxoSmithKline's takeover bid after the UK-based giant sweetened its offer, adding $1.25 per share to its previous offer of $13 a share. At $14.25 per share, which is what the companies have finally closed on, HGS is valued at about $3.6 billion.
You may also be interested in...
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.
One pilot target domestic manufacturers of finished drugs and another foreign manufacturers of APIs. As an incentive to participate, companies assigned high scores will be accorded regulatory flexibility. Also, participants that disclose facility ratings could “benefit from a competitive advantage.”